IP Library Granted Patent US 8,546,090
Granted Patent B2
US 8,546,090 · App. 13/646,148 · Granted Oct 1, 2013

SIRT4 activities

Inventors: Marcia C. Haigis (Stoneham, MA); Leonard P. Guarente (Newton, MA)
Assignee: Massachusetts Instittue of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,090
App. No.
13/646,148
Granted
Oct 1, 2013
Kind
B2
Abstract

Methods of modulating insulin secretion and treating metabolic disorders by modulating the expression or activity of Sirt4 are provided.

Claims (13)

1. A method of modulating insulin secretion in response to glucose, comprising administering an agent to modulate the expression or activity of Sirt4 in an insulin-secreting cell.

2. The method of claim 1 , wherein insulin secretion is increased by decreasing the expression or activity of Sirt4.

3. The method of claim 1 , wherein insulin secretion is decreased by increasing the expression or activity of Sirt4.

4. The method of claim 1 , wherein insulin secretion is modulated in vitro.

5. The method of claim 1 , wherein insulin secretion is modulated in a subject.

6. A method of treating a metabolic disorder, comprising administering to a subject an agent that modulates the expression or activity of Sirt4 in an amount effective to treat the metabolic disorder.

7. The method of claim 6 , wherein the metabolic disorder includes at least one of diabetes, insulin resistance, metabolic syndrome and pre-diabetes.

8. The method of claim 6 , wherein the levels of Sirt4 are modulated in an insulin-secreting cell.

9. The method of claim 6 , wherein the agent is an antagonistic nucleic acid that reduces Sirt4 expression.

10. The method of claim 6 , wherein the agent comprises an siRNA that targets Sirt4 mRNA.

11. A method of treating a symptom of a neurodegenerative disorder, comprising administering to a subject a compound that increases the expression or activity of Sirt4 in an amount effective to treat the neurodegenerative disorder.

12. The method of claim 11 , wherein the neurodegenerative disorder involves accumulation of β-amyloid peptide.

13. The method of claim 11 , wherein the neurodegenerative disorder is Alzheimer's disease.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 6, 2012
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029246/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2012
From: GUARENTE, LEONARD P.; HAIGIS, MARCIA C.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 029159/0937 →
Continuity (4)
Continuation 12851225 · Aug 5, 2010
Continuation 11409170 · Apr 21, 2006
Provisional Application 60673565 · Apr 21, 2005
Related Publication 20130096179A1 · Apr 18, 2013